Tetra Radar · FDA Approvals · Decision date
Praxis Precision Medicines, Inc.: FDA decision date
Praxis Precision Medicines, Inc. (PRAX) · 27 September 2026
Food and Drug Administration (the “FDA”) notified the Company that it has extended by three months the review period for its New Drug Application (“NDA”) for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (“DEEs”), setting an updated PDUFA target action date from September 27, 2026 to December 27, 2026.
Source: 8-K of 29 June 2026
The date has passed; Tetra Radar has not recorded an approval.
A PDUFA date is the date by which the FDA has said it will decide on an application. Dates can move, and a decision is not an approval. Tetra Radar observes public information for research purposes. It does not provide investment advice.